Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage.
Giant cell arteritis
Glucocorticoids
Polymyalgia rheumatica
Positron emission tomography
Reduced vision
Symptom flare-up
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
19
08
2020
accepted:
12
10
2020
pubmed:
29
10
2020
medline:
16
11
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
The objective of the study is to investigate the clinical characteristics and long-term prognosis including flares and organ damage in patients with giant cell arteritis (GCA) from a tertiary referral centre and compare these features in different subgroups. In this retrospective observational study, patients with GCA who were followed up in our vasculitis clinic between 1998 and 2018 were evaluated by a predefined protocol. Patients with and without cranial symptoms were compared for clinical and laboratory features, flares and permanent damage findings. Vasculitis Damage Index and Large Vessel Vasculitis Index of Damage were used for damage assessment. Records of 89 patients (median follow-up time 46 months) were analysed; mean time to diagnosis after initial symptom was longer in patients with acute vision loss (11 ± 4 vs. 4.8 ± 1.1 months p = 0.002). EGG (n = 19) was younger (63 ± 2 vs. 69 ± 1 years old p = 0.01); had higher mean CRP (141.8 ± 107.3 vs. 76.6 ± 67.9 mg/dL p = 0.023) and ESR (120.8 ± 25.1 vs. 99.3 ± 24.3 mm/h p = 0.004) at diagnosis. PET-CT detected large vessel vasculitis in 42/48 (87.5%) cases of the entire cohort. Thirty-one patients had flares and proportion of flared patients was significantly higher in patients with cranial symptoms. At least one damage item (DI) was present in 54 (60.7%) patients. The development of damage was found to be associated with flares. Evaluation of our cohort revealed the importance of early diagnosis for prevention of vision loss in GCA. Patients without cranial symptoms were younger, present with higher inflammatory response and for these, PET-CT was the main diagnostic tool. Relapse rate was higher in patients with cranial symptoms. Flares and accompanying corticosteroid treatment may contribute to organ damage in GCA.
Identifiants
pubmed: 33113000
doi: 10.1007/s00296-020-04730-1
pii: 10.1007/s00296-020-04730-1
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-448Références
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11
doi: 10.1002/art.37715
Gonzalez-gay MA, Vazquez-rodriguez TR, Lopez-diaz MJ, Miranda-filloy JA, Gonzalez-juanatey C, Martin J et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61(10):1454–1461
doi: 10.1002/art.24459
Brekke LK, Diamantopoulos AP, Fevang BT, Abetamus J, Espero E, Gjesdal CG (2017) Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Res Ther 19(1):278
doi: 10.1186/s13075-017-1479-6
Gonzalez-gay MA, Miranda-filloy JA, Lopez-diaz MJ, Perez-alvarez R, Gonzalez-juanatey C, Sanchez-andrade A et al (2007) Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 86(2):61–68
doi: 10.1097/md.0b013e31803d1764
Pamuk ON, Donmez S, Karahan B, Pamuk GE, Cakir N (2009) Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data. Clin Exp Rheumatol 27(5):830–833
pubmed: 19917168
Salvarani C, Gabriel SE, O’fallon WM, Hunder GG (1995) The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 123(3):192–194
doi: 10.7326/0003-4819-123-3-199508010-00006
Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K et al (2003) Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 49(4):594–598
doi: 10.1002/art.11195
Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128
doi: 10.1002/art.1780330810
Ponte C, Grayson P, Suppiah R, Robson J, Gribbons K, Craven A et al (2019) 007. °Classification criteria for large-vessel vasculitis. Rheumatology. https://doi.org/10.1093/rheumatology/kez058.017
doi: 10.1093/rheumatology/kez058.017
Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55(1):66–70
doi: 10.1093/rheumatology/kev289
De Boysson H, Lambert M, Liozon E, Boutemy J, Maigne G, Ollivier Y et al (2016) Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern. Medicine (Baltimore) 95(26):e3818
doi: 10.1097/MD.0000000000003818
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D et al (2017) Trial of Tocilizumab in giant-cell arteritis. New Engl J Med 377(4):317–328
doi: 10.1056/NEJMoa1613849
Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M et al (2016) The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20(90):1–238
doi: 10.3310/hta20900
Hellmich B, Agueda A, Monti S, Buttgereit F, De Boysson H, Brouwer E, et al (2019) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis
Laskou F, Koduri G, Lever E, Stapleton P, Dasgupta B (2017) 330 °Flare rates in giant cell arteritis: a single-centre long-term retrospective study. Rheumatology. https://doi.org/10.1093/rheumatology/kex062.337
doi: 10.1093/rheumatology/kex062.337
Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P et al (2016) Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum 46(2):246–252
doi: 10.1016/j.semarthrit.2016.05.009
Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19(5):495–501
pubmed: 11579707
Mahr AD, Jover JA, Spiera RF, Hernandez-garcia C, Fernandez-Gutierrez B, Lavalley MP et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797
doi: 10.1002/art.22754
Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A et al (2017) Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res (Hoboken) 69(3):430–438
doi: 10.1002/acr.22942
Salvarani C, Crowson CS, O’fallon WM, Hunder GG, Gabriel SE (2004) Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 51(2):264–268
doi: 10.1002/art.20227
Vodopivec I, Rizzo JF (2018) 3
doi: 10.1093/rheumatology/kex428
Li L, Neogi T, Jick S (2017) Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink. Rheumatology (Oxford) 56(5):753–762
Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA et al (2018) Evaluation of damage in giant cell arteritis. Rheumatology (Oxford) 57(2):322–328
doi: 10.1093/rheumatology/kex397
Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380
doi: 10.1002/art.1780400222
Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B et al (2019) 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann Rheum Dis 78(9):1160–1166
doi: 10.1136/annrheumdis-2018-214755
Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C et al (2012) 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 64(4):943–954
doi: 10.1002/art.34356
Salvarani C, Pipitone N, Versari A, Hunder GG (2012) Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 8(9):509–521
doi: 10.1038/nrrheum.2012.97
Cunha BA, Lortholary O, Cunha CB (2015) Fever of unknown origin: a clinical approach. Am J Med 128(10):1138 ((e1–e15))
doi: 10.1016/j.amjmed.2015.06.001
Rubenstein E, Maldini C, Gonzalez-chiappe S, Chevret S, Mahr A (2019) Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology. https://doi.org/10.1093/rheumatology/kez058.051
doi: 10.1093/rheumatology/kez058.051
Font C, Cid MC, Coll-vinent B, Lopez-soto A, Grau JM (1997) Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 36(2):251–254
doi: 10.1093/rheumatology/36.2.251
Cid MC, Font C, Oristrell J, De la Sierra A, Coll-vinent B, Lopez-soto A et al (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41(1):26–32
doi: 10.1002/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0
Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ (1997) Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40(1):19–26
doi: 10.1002/art.1780400105
Weyand CM, Younge BR, Goronzy JJ (2011) IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23(1):43–49
doi: 10.1097/BOR.0b013e32833ee946
Best JH, Kong AM, Unizony S, Tran O, Michalska M (2019) Risk of potential glucocorticoid-related adverse events in patients with giant cell arteritis: results from a USA-based electronic health records database. Rheumatol Ther 6(4):599–610
doi: 10.1007/s40744-019-00180-9
Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A, Pipitone N et al (2019) Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. Rheumatology (Oxford) 58(4):609–616
doi: 10.1093/rheumatology/key325
Nesher G, Poltorak V, Hindi I, Nesher R, Dror Y, Orbach H et al (2019) Survival of patient with giant cell arteritis: impact of vision loss and treatment with aspirin. Autoimmun Rev 18(8):831–834
doi: 10.1016/j.autrev.2019.06.003